INS and type 1 diabetes mellitus: Such genotypes were associated with anextremely high disease risk for siblings (77).Apart from primary prevention of type 1 diabetes, future SSO-based therapeutics mightbe applicable to patients with significant residual β-cell activity atdiagnosis and to those who are eligible to receive β-cell transplants and maybenefit from increased intron-mediated enhancement of proinsulin expression fromtransplanted cells.